EUVIMEDEUVIMED entdecken
Multizentrische Studie

CT-guided High-Dose-Rate Brachytherapy versus Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma

Timo A Auer iD, Lukas Müller iD, Daniel Schulze iD, Melina Anhamm iD, Dominik Bettinger iD, Verena Steinle, Johannes Haubold iD, David Zopfs iD, Daniel Pinto Dos Santos iD, Michel Eisenblätter, Bernhard Gebauer iD, Roman Kloeckner iD und 1 weitere

Radiology · 2024

DOI: 10.1148/radiol.232044 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Radiology, 2024. Verfasst von Timo A Auer und 12 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Radiology, Charité-Universitätsmedizin Berlin, Charité Campus Mitte, Charitéplatz 1, 10117 Berlin, Germany (T.A.A., M.A., B.G.…. Hauptthemen laut MEDLINE: Brachytherapy, Carcinoma, Hepatocellular, Chemoembolization, Therapeutic, Liver Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

CT-guided high-dose-rate (HDR) brachytherapy (hereafter, HDR brachytherapy) has been shown to be safe and effective for patients with unresectable hepatocellular carcinoma (HCC), but studies comparing this therapy with other local-regional therapies are scarce.

Purpose

To compare patient outcomes of HDR brachytherapy and transarterial chemoembolization (TACE) in patients with unresectable HCC. Materials and Methods This multi-institutional retrospective study included consecutive treatment-naive adult patients with unresectable HCC who underwent either HDR brachytherapy or TACE between January 2010 and December 2022. Overall survival (OS) and progression-free survival (PFS) were compared between patients matched for clinical and tumor characteristics by propensity score matching. Not all patients who underwent TACE had PFS available; thus, a different set of patients was used for PFS and OS analysis for this treatment. Hazard ratios (HRs) were calculated from Kaplan-Meier survival curves.

Results

After propensity matching, 150 patients who underwent HDR brachytherapy (median age, 71 years [IQR, 63-77 years]; 117 males) and 150 patients who underwent TACE (OS analysis median age, 70 years [IQR, 63-77 years]; 119 male; PFS analysis median age, 68 years [IQR: 63-76 years]; 119 male) were analyzed. Hazard of death was higher in the TACE versus HDR brachytherapy group (HR, 4.04; P < .001). Median estimated PFS was 32.8 months (95% CI: 12.5, 58.7) in the HDR brachytherapy group and 11.6 months (95% CI: 4.9, 22.7) in the TACE group. Hazard of disease progression was higher in the TACE versus HDR brachytherapy group (HR, 2.23; P < .001).

Conclusion

In selected treatment-naive patients with unresectable HCC, treatment with CT-guided HDR brachytherapy led to improved OS and PFS compared with TACE. © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Chapiro in this issue.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BrachytherapyCarcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsAdultAgedHumansMaleRetrospective StudiesTomography, X-Ray Computed

Autor:innen und Institutionen

  • From the Department of Radiology, Charité-Universitätsmedizin Berlin, Charité Campus Mitte, Charitéplatz 1, 10117 Berlin, Germany (T.A.A., M.A., B.G., F.C.); Berlin Institute of Health, Berlin, Germany (T.A.A., F.C.); D…

ORCID-Profile: Timo A Auer, Lukas Müller, Daniel Schulze, Melina Anhamm, Dominik Bettinger, Johannes Haubold, David Zopfs, Daniel Pinto Dos Santos, Bernhard Gebauer, Roman Kloeckner, Federico Collettini

Zitieren

APA

Auer, T. A., Müller, L., Schulze, D., Anhamm, M., Bettinger, D., Steinle, V., Haubold, J., Zopfs, D., Pinto Dos Santos, D., Eisenblätter, M., Gebauer, B., Kloeckner, R., & Collettini, F. (2024). CT-guided High-Dose-Rate Brachytherapy versus Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma. Radiology. https://doi.org/10.1148/radiol.232044

Vancouver

Auer TA, Müller L, Schulze D, Anhamm M, Bettinger D, Steinle V, et al. CT-guided High-Dose-Rate Brachytherapy versus Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma. Radiology. 2024. doi:10.1148/radiol.232044

BibTeX
@article{Auer2024,
  author = {Auer, Timo A and Müller, Lukas and Schulze, Daniel and Anhamm, Melina and Bettinger, Dominik and Steinle, Verena and Haubold, Johannes and Zopfs, David and Pinto Dos Santos, Daniel and Eisenblätter, Michel and Gebauer, Bernhard and Kloeckner, Roman and Collettini, Federico},
  title = {CT-guided High-Dose-Rate Brachytherapy versus Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma},
  journal = {Radiology},
  year = {2024},
  doi = {10.1148/radiol.232044}
}
Kostenlos starten →